Amedeo Smart

Free Medical Literature Service

 

Amedeo

Prostate Cancer
  Free Subscription

Articles published in
Br J Cancer
    July 2026
  1. TIEFENBACHER A, Gudenus M, Valcanover D, Neudert B, et al
    Adipose triglyceride lipase driven lipolysis as a targetable metabolic vulnerability in prostate cancer with intrinsic metabolic inflexibility.
    Br J Cancer. 2026 Jul 23. doi: 10.1038/s41416-026-03545.
    >> Share

  2. PENG Z, Hodgson K, Fisher M, Mei S, et al
    Targeting Siglec-engaging immunosuppressive sialoglycans to suppress prostate cancer bone metastasis.
    Br J Cancer. 2026 Jul 13. doi: 10.1038/s41416-026-03544.
    >> Share

  3. ELSESY ME, Moustafa A, Oh-Hohenhorst SJ, Muller C, et al
    Functional and omics-based rationale for the induction of BRCAness by androgen receptor pathway inhibitors to sensitize prostate cancer to PARP inhibition, regardless of HRR status.
    Br J Cancer. 2026 Jul 7. doi: 10.1038/s41416-026-03518.
    >> Share

    June 2026
  4. YOON HS, Shu XO, Wu J, Sanderson M, et al
    Circulating metabolite biomarkers associated with prostate cancer risk in Black Americans: findings from the Southern Community Cohort Study.
    Br J Cancer. 2026 Jun 27. doi: 10.1038/s41416-026-03520.
    >> Share

    May 2026
  5. WALDRON NR, Silva D, Westaby D, Jimenez-Vacas J, et al
    Decoding the Raf-Mek-Erk-Rsk pathway in prostate cancer: from molecular mechanisms to clinical opportunities.
    Br J Cancer. 2026 May 13. doi: 10.1038/s41416-026-03441.
    >> Share

  6. YANG K, Thong MSY, Doege D, Koch-Gallenkamp L, et al
    Diabetes mellitus and health-related quality of life in long-term survivors of breast, colorectal or prostate cancer: a population-based prospective study.
    Br J Cancer. 2026 May 13. doi: 10.1038/s41416-026-03463.
    >> Share

    April 2026
  7. MAHARAJ MSN, Mertens-Walker I, Lisle JE, Herington A, et al
    SUMOylation of EphB4 enhances its stability in prostate cancer.
    Br J Cancer. 2026 Apr 15. doi: 10.1038/s41416-026-03442.
    >> Share

  8. KONDRUP K, Iisager L, Salachan PV, Norgaard M, et al
    Genome-wide methylome profiling of cell-free DNA enables prognostication of patients with castration-resistant prostate cancer.
    Br J Cancer. 2026 Apr 10. doi: 10.1038/s41416-026-03432.
    >> Share

    March 2026
  9. CRABB SJ, Morgan A, Stefanopoulou E, Fleure L, et al
    Self-help cognitive behavioural therapy for hot flushes and night sweats during androgen deprivation therapy for prostate cancer: the MANCAN2 randomized controlled trial.
    Br J Cancer. 2026 Mar 24. doi: 10.1038/s41416-026-03375.
    >> Share

  10. TURNHAM DJ, French R, Frame FM, Meniel VS, et al
    Inhibition of c-FLIP alongside TRAIL treatment suppresses prostate cancer stem cell activity.
    Br J Cancer. 2026 Mar 3. doi: 10.1038/s41416-026-03359.
    >> Share

  11. DIXON KM, Lui GYL, Kovacevic Z, Zhang D, et al
    Correction to: Dp44mT targets the AKT, TGF-beta and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells.
    Br J Cancer. 2026 Mar 2. doi: 10.1038/s41416-026-03353.
    >> Share

  12. YANG J, Ryniawec JM, de Oliveira Pessoa D, Coope MR, et al
    Transient centrosome loss in cultured prostate epithelial cells induces chromosomal instability to produce an oncogenic genotype that correlates with poor clinical outcomes.
    Br J Cancer. 2026;134:924-938.
    >> Share

    January 2026
  13. FULLER H, Agasaro OP, Guevara JM, Darst BF, et al
    Pre-diagnostic circulating untargeted metabolomics and risk of overall and clinically significant prostate cancer: a systematic review and meta-analysis.
    Br J Cancer. 2026 Jan 10. doi: 10.1038/s41416-025-03312.
    >> Share

  14. VLACHOS G, Moser T, Lazzeri I, Moser MJ, et al
    Functional footprints of homologous recombination deficiency in prostate cancer revealed by ctDNA fragmentation and transcription factor accessibility.
    Br J Cancer. 2026 Jan 9. doi: 10.1038/s41416-025-03301.
    >> Share

    December 2025
  15. NAIR-SHALLIKER V, Smith DP, Gebski V, Patel MI, et al
    High-dose vitamin D supplementation and prostate cancer progression: a phase II randomised trial in localised prostate cancer cases with intermediate risk of progression (ProsD).
    Br J Cancer. 2025 Dec 21. doi: 10.1038/s41416-025-03278.
    >> Share

  16. LIN R, Un H, Kang Y, Lei J, et al
    Senescence-related gene signature predicts prostate cancer progression and identifies PCNA as a therapeutic target via multi-omics machine learning integration.
    Br J Cancer. 2025 Dec 18. doi: 10.1038/s41416-025-03309.
    >> Share

  17. WIDDING JL, Stroomberg HV, Dalton SO, Brasso K, et al
    The association between lower urinary tract symptoms and urinary tract infections, and subsequent prostate cancer workup: a nationwide population-based case-control study.
    Br J Cancer. 2025 Dec 3. doi: 10.1038/s41416-025-03288.
    >> Share

    November 2025
  18. ZHU Y, Zarean E, Li DL, O'Reilly RL, et al
    Tumour-based epigenetic signatures as markers of prostate cancer aggressiveness after radical prostatectomy.
    Br J Cancer. 2025 Nov 20. doi: 10.1038/s41416-025-03257.
    >> Share

  19. QIU C, Wang X, Francia G, Casiano CA, et al
    A panel of four autoantibodies to tumour-associated antigens in patients with prostate cancer and its potential for multi-cancer detection.
    Br J Cancer. 2025 Nov 18. doi: 10.1038/s41416-025-03242.
    >> Share

  20. ZUCKER K, McInerney C, Glaser A, Baxter P, et al
    Why NHS hospital co-morbidity research may be wrong: how clinical coding fails to identify the impact of diabetes mellitus on cancer survival.
    Br J Cancer. 2025;133:1137-1144.
    >> Share

    October 2025
  21. KLOOTS ISH, Slootbeek PHJ, Tolmeijer SH, van Wilpe S, et al
    Molecular reflex testing in patients with early metastatic castration-resistant prostate cancer within the PROMPT-study.
    Br J Cancer. 2025 Oct 31. doi: 10.1038/s41416-025-03243.
    >> Share

  22. NIKHIL K, Haymour HS, Kamra M, Shah K, et al
    Correction: Phosphorylation-dependent regulation of SPOP by LIMK2 promotes castration-resistant prostate cancer.
    Br J Cancer. 2025 Oct 9. doi: 10.1038/s41416-025-03212.
    >> Share

  23. CHANG YH, Bresnahan ST, Taylor Head S, Harrison TA, et al
    Isoform-level analyses of 6 cancers uncover extensive genetic risk mechanisms undetected at the gene-level.
    Br J Cancer. 2025;133:874-885.
    >> Share

    September 2025
  24. MAY M, Gilfrich C, Enzinger B, Brookman-May S, et al
    Exercise oncology in prostate cancer: from observational insight to prescriptive precision.
    Br J Cancer. 2025 Sep 16. doi: 10.1038/s41416-025-03205.
    >> Share

  25. HUANG H, Benzonana LL, Zhao H, Watts HR, et al
    Correction to: Prostate cancer cell malignancy via modulation of HIF-1alpha pathway with isoflurane and propofol alone and in combination.
    Br J Cancer. 2025 Sep 5. doi: 10.1038/s41416-025-03175.
    >> Share

    July 2025
  26. AN KY, Jeon JY, Arthuso FZ, Wang Q, et al
    Postdiagnosis physical activity is associated with improved survival in prostate cancer patients treated with surgery but not with radiation therapy.
    Br J Cancer. 2025 Jul 23. doi: 10.1038/s41416-025-03123.
    >> Share

  27. FLAHERTY RL, Falcinelli M, Hesketh AR, Patel BA, et al
    Biomarkers of psychological stress are associated with increased susceptibility to the development of breast and prostate cancer in BRCA1/2 mutation carriers.
    Br J Cancer. 2025 Jul 2. doi: 10.1038/s41416-025-03085.
    >> Share

    April 2025
  28. LI X, Mamouni K, Zhao R, Bai L, et al
    Novel Skp1 inhibitor has potent preclinical efficacy against castration-resistant prostate cancer.
    Br J Cancer. 2025 Apr 19. doi: 10.1038/s41416-025-02993.
    >> Share

  29. HARTLEY A, Galbraith LCA, Shaw R, Tibbo A, et al
    Loss of ARID1A accelerates prostate tumourigenesis with a proliferative collagen-poor phenotype through co-operation with AP1 subunit cFos.
    Br J Cancer. 2025;132:502-512.
    >> Share

    March 2025
  30. LI GX, Ma B, Zhang S, Liu R, et al
    EphB4-ephrin-B2 are targets in castration resistant prostate cancer.
    Br J Cancer. 2025 Mar 5. doi: 10.1038/s41416-025-02942.
    >> Share

  31. O'SULLIVAN JM, Heinrich D, Castro E, George S, et al
    Alkaline phosphatase decline and pain response as predictors of overall survival benefit in patients treated with radium-223: a post hoc analysis of the REASSURE study.
    Br J Cancer. 2025;132:354-360.
    >> Share

    February 2025
  32. LIN SC, Cheng YS, Lin YS, Nguyen TMH, et al
    The long noncoding RNA lncZBTB10 facilitates AR function via S-palmitoylation to promote prostate cancer progression and abiraterone resistance.
    Br J Cancer. 2025 Feb 16. doi: 10.1038/s41416-025-02938.
    >> Share

  33. VAN DER KLEIJ MBA, Meertens M, Groenland SL, Kordes S, et al
    Feasibility and efficacy of therapeutic drug monitoring of abiraterone in metastatic castration resistant prostate cancer patients.
    Br J Cancer. 2025 Feb 11. doi: 10.1038/s41416-025-02954.
    >> Share

  34. WANG R, Wang S, Mi Y, Huang T, et al
    Elevated serum levels of GPX4, NDUFS4, PRDX5, and TXNRD2 as predictive biomarkers for castration resistance in prostate cancer patients: an exploratory study.
    Br J Cancer. 2025 Feb 3. doi: 10.1038/s41416-025-02947.
    >> Share

    December 2024
  35. LUO L, Wang R, Bai L, Shang J, et al
    The accuracy of fluorine 18-labelled prostate-specific membrane antigen PET/CT and MRI for diagnosis of prostate cancer in PSA grey zone.
    Br J Cancer. 2024 Dec 19. doi: 10.1038/s41416-024-02934.
    >> Share

  36. LIU C, Reger M, Fan H, Wang J, et al
    Dietary intake of isoflavones and coumestrol and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Br J Cancer. 2024 Dec 16. doi: 10.1038/s41416-024-02929.
    >> Share

  37. CHEN M, Zhou S, He X, Wen H, et al
    Identification of diagnostic biomarkers in prostate cancer-related fatigue by construction of predictive models and experimental validation.
    Br J Cancer. 2024 Dec 15. doi: 10.1038/s41416-024-02922.
    >> Share

    October 2024
  38. RAHMAN R, Rahaman MH, Hanson AR, Choo N, et al
    Author Correction: CDK9 inhibition constrains multiple oncogenic transcriptional and epigenetic pathways in prostate cancer.
    Br J Cancer. 2024 Oct 24. doi: 10.1038/s41416-024-02862.
    >> Share

  39. SHEN M, Garcia-Marques F, Muruganantham A, Liu S, et al
    Identification of a 5-gene signature panel for the prediction of prostate cancer progression.
    Br J Cancer. 2024 Oct 14. doi: 10.1038/s41416-024-02854.
    >> Share

    September 2024
  40. CHOW ST, Fan J, Zhang X, Wang Y, et al
    Nuclear receptor TLX functions to promote cancer stemness and EMT in prostate cancer via its direct transactivation of CD44 and stem cell-regulatory transcription factors.
    Br J Cancer. 2024 Sep 26. doi: 10.1038/s41416-024-02843.
    >> Share

  41. WANG T, Wang X, Ding G, Liu H, et al
    Efficacy and safety evaluation of androgen deprivation therapy-based combinations for metastatic castration-sensitive prostate cancer: a systematic review and network meta-analysis.
    Br J Cancer. 2024 Sep 2. doi: 10.1038/s41416-024-02823.
    >> Share

    August 2024
  42. NTURUBIKA BD, Guardia CM, Gershlick DC, Logan JM, et al
    Altered expression of vesicular trafficking machinery in prostate cancer affects lysosomal dynamics and provides insight into the underlying biology and disease progression.
    Br J Cancer. 2024 Aug 31. doi: 10.1038/s41416-024-02829.
    >> Share

  43. RAHMAN R, Rahaman MH, Hanson AR, Choo N, et al
    CDK9 inhibition inhibits multiple oncogenic transcriptional and epigenetic pathways in prostate cancer.
    Br J Cancer. 2024 Aug 8. doi: 10.1038/s41416-024-02810.
    >> Share

    July 2024
  44. LIN BB, Huang Q, Yan B, Liu M, et al
    An 18-gene signature of recurrence-associated endothelial cells predicts tumor progression and castration resistance in prostate cancer.
    Br J Cancer. 2024 Jul 12. doi: 10.1038/s41416-024-02761.
    >> Share

  45. PUJANA-VAQUERIZO M, Bozal-Basterra L, Carracedo A
    Metabolic adaptations in prostate cancer.
    Br J Cancer. 2024 Jul 5. doi: 10.1038/s41416-024-02762.
    >> Share

  46. CYLL K, Skaaheim Haug E, Pradhan M, Vlatkovic L, et al
    DNA ploidy and PTEN as biomarkers for predicting aggressive disease in prostate cancer patients under active surveillance.
    Br J Cancer. 2024 Jul 3. doi: 10.1038/s41416-024-02780.
    >> Share

    June 2024
  47. ARMAKOLAS A, Alevizopoulos N, Stathaki M, Petraki C, et al
    Anti-PEc: Development of a novel monoclonal antibody against prostate cancer.
    Br J Cancer. 2024 Jun 20. doi: 10.1038/s41416-024-02713.
    >> Share

    March 2024
  48. ZHANG Y, Stopsack KH, Wu K, Song M, et al
    Multivitamin use after diagnosis and prostate cancer survival among men with nonmetastatic prostate cancer.
    Br J Cancer. 2024 Mar 15. doi: 10.1038/s41416-024-02651.
    >> Share

  49. GNANAPRAGASAM V
    Shifting the paradigm in the management of early prostate cancer.
    Br J Cancer. 2024 Mar 6. doi: 10.1038/s41416-024-02641.
    >> Share

    February 2024
  50. EBERLEIN C, Williamson SC, Hopcroft L, Ros S, et al
    Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer.
    Br J Cancer. 2024 Feb 23. doi: 10.1038/s41416-024-02614.
    >> Share

  51. LIU Q, Zhang Y, Vaselkiv JB, Mucci LA, et al
    A prospective study of birth weight and prostate cancer risk and mortality in the Health Professionals Follow-up Study.
    Br J Cancer. 2024 Feb 22. doi: 10.1038/s41416-024-02593.
    >> Share

  52. CONSTANTIN TA, Varela-Carver A, Greenland KK, de Almeida GS, et al
    Correction: The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer.
    Br J Cancer. 2024 Feb 14. doi: 10.1038/s41416-024-02606.
    >> Share

  53. O'MALLEY DE, Raspin K, Melton PE, Burdon KP, et al
    Acquired copy number variation in prostate tumours: a review of common somatic copy number alterations, how they are formed and their clinical utility.
    Br J Cancer. 2024;130:347-357.
    >> Share

    January 2024
  54. MAH CY, Nguyen ADT, Niijima T, Helm M, et al
    Peroxisomal beta-oxidation enzyme, DECR2, regulates lipid metabolism and promotes treatment resistance in advanced prostate cancer.
    Br J Cancer. 2024 Jan 12. doi: 10.1038/s41416-023-02557.
    >> Share

    December 2023
  55. FRITZ J, Jochems SHJ, Bjorge T, Wood AM, et al
    Body mass index, triglyceride-glucose index, and prostate cancer death: a mediation analysis in eight European cohorts.
    Br J Cancer. 2023 Dec 12. doi: 10.1038/s41416-023-02526.
    >> Share

    November 2023
  56. ZHAO JL, Antonarakis ES, Cheng HH, George DJ, et al
    Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC).
    Br J Cancer. 2023 Nov 18. doi: 10.1038/s41416-023-02487.
    >> Share

  57. SHEN J, Chowdhury S, Agarwal N, Karsh LI, et al
    Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN.
    Br J Cancer. 2023 Nov 11. doi: 10.1038/s41416-023-02492.
    >> Share

  58. AHMAD AS, Offman J, Delon C, North BV, et al
    Years of life lost due to cancer in the United Kingdom from 1988 to 2017.
    Br J Cancer. 2023;129:1558-1568.
    >> Share

  59. CAMERON JM, Sala A, Antoniou G, Brennan PM, et al
    A spectroscopic liquid biopsy for the earlier detection of multiple cancer types.
    Br J Cancer. 2023;129:1658-1666.
    >> Share

  60. SHEN M, Liu S, Toland A, Hsu EC, et al
    ACAA2 is a novel molecular indicator for cancers with neuroendocrine phenotype.
    Br J Cancer. 2023;129:1818-1828.
    >> Share

    October 2023
  61. FENG X, Zhang Y, Vaselkiv JB, Li R, et al
    Modifiable risk factors for subsequent lethal prostate cancer among men with an initially negative prostate biopsy.
    Br J Cancer. 2023 Oct 28. doi: 10.1038/s41416-023-02472.
    >> Share

  62. TURPIN A, Delliaux C, Parent P, Chevalier H, et al
    Fascin-1 expression is associated with neuroendocrine prostate cancer and directly suppressed by androgen receptor.
    Br J Cancer. 2023 Oct 24. doi: 10.1038/s41416-023-02449.
    >> Share

  63. GULLIVER C, Huss S, Semjonow A, Baillie GS, et al
    Loss of PDE4D7 expression promotes androgen independence, neuroendocrine differentiation and alterations in DNA repair: implications for therapeutic strategies.
    Br J Cancer. 2023;129:1462-1476.
    >> Share

    September 2023
  64. HOU Y, Jiang KW, Wang LL, Zhi R, et al
    Biopsy-free AI-aided precision MRI assessment in prediction of prostate cancer biochemical recurrence.
    Br J Cancer. 2023 Sep 27. doi: 10.1038/s41416-023-02441.
    >> Share

  65. HINNEH JA, Gillis JL, Mah CY, Irani S, et al
    Targeting hyaluronan-mediated motility receptor (HMMR) enhances response to androgen receptor signalling inhibitors in prostate cancer.
    Br J Cancer. 2023 Sep 6. doi: 10.1038/s41416-023-02406.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016